RxDoctor Payments Data

Roofan Alsayegh, MD

Hospitalist · West Hills, CANPI 1477841641

Payments from drug & device makers

$749in general payments, 2019–2025

Across 15 payments — averaging $49.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$153
  • Neurocrine Biosciences, Inc.$140
  • AstraZeneca$125
  • AbbVie$120
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$93
  • Pfizer$89
  • plus $29 from 1 others

What the payments were for

  • Food & beverage$749100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$749 in reported general payments places this provider in the 85th percentile of 2,469 hospitalist providers in California.

See all hospitalist providers in California

Medicare billing

Part B allowed, 2024
$617,874
Medicare patients
945
Services billed
5,885

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban379$127,966
PromactaEltrombopag Olamine13$100,376
XareltoRivaroxaban73$22,286
EntrestoSacubitril/Valsartan47$18,732
RytaryCarbidopa/Levodopa33$16,647
JanuviaSitagliptin Phosphate34$15,390
OzempicSemaglutide14$13,623
FarxigaDapagliflozin Propanediol19$11,885
BrilintaTicagrelor50$11,296
JardianceEmpagliflozin29$9,578
Atorvastatin Calcium598$8,309
TrintellixVortioxetine Hydrobromide37$7,885
InvokanaCanagliflozin20$5,980
GemtesaVibegron11$5,379
ErtapenemErtapenem Sodium15$4,964

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$89$127,966379 claims
NovartisPromacta, Entresto$153$119,10860 claims
AstraZenecaFarxiga, Brilinta$125$23,18169 claims
AbbVieLumigan$120$2,83511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,469 hospitalist providers in California.

Other hospitalist in West Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →